180 related articles for article (PubMed ID: 27966451)
1. FGFR4 polymorphic alleles modulate mitochondrial respiration: A novel target for somatostatin analog action in pituitary tumors.
Ezzat S; Wang R; Pintilie M; Asa SL
Oncotarget; 2017 Jan; 8(2):3481-3494. PubMed ID: 27966451
[TBL] [Abstract][Full Text] [Related]
2. The FGFR4-G388R polymorphism promotes mitochondrial STAT3 serine phosphorylation to facilitate pituitary growth hormone cell tumorigenesis.
Tateno T; Asa SL; Zheng L; Mayr T; Ullrich A; Ezzat S
PLoS Genet; 2011 Dec; 7(12):e1002400. PubMed ID: 22174695
[TBL] [Abstract][Full Text] [Related]
3. FGFR4 polymorphic variants modulate phenotypic features of Cushing disease.
Nakano-Tateno T; Tateno T; Hlaing MM; Zheng L; Yoshimoto K; Yamada S; Asa SL; Ezzat S
Mol Endocrinol; 2014 Apr; 28(4):525-33. PubMed ID: 24625004
[TBL] [Abstract][Full Text] [Related]
4. Targeting N-cadherin through fibroblast growth factor receptor-4: distinct pathogenetic and therapeutic implications.
Ezzat S; Zheng L; Winer D; Asa SL
Mol Endocrinol; 2006 Nov; 20(11):2965-75. PubMed ID: 16857743
[TBL] [Abstract][Full Text] [Related]
5. FGFR4 GLY388 isotype suppresses motility of MDA-MB-231 breast cancer cells by EDG-2 gene repression.
Stadler CR; Knyazev P; Bange J; Ullrich A
Cell Signal; 2006 Jun; 18(6):783-94. PubMed ID: 16109476
[TBL] [Abstract][Full Text] [Related]
6. The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy.
Serra S; Zheng L; Hassan M; Phan AT; Woodhouse LJ; Yao JC; Ezzat S; Asa SL
Cancer Res; 2012 Nov; 72(22):5683-91. PubMed ID: 22986737
[TBL] [Abstract][Full Text] [Related]
7. FGFR4 Gly388Arg Polymorphism Affects the Progression of Gastric Cancer by Activating STAT3 Pathway to Induce Epithelial to Mesenchymal Transition.
Ye Y; Li J; Jiang D; Li J; Xiao C; Li Y; Han C; Zhao C
Cancer Res Treat; 2020 Oct; 52(4):1162-1177. PubMed ID: 32599983
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to extracellular matrix degradation.
Sugiyama N; Varjosalo M; Meller P; Lohi J; Hyytiäinen M; Kilpinen S; Kallioniemi O; Ingvarsen S; Engelholm LH; Taipale J; Alitalo K; Keski-Oja J; Lehti K
Cancer Res; 2010 Oct; 70(20):7851-61. PubMed ID: 20876804
[TBL] [Abstract][Full Text] [Related]
9. Germline variant FGFR4 p.G388R exposes a membrane-proximal STAT3 binding site.
Ulaganathan VK; Sperl B; Rapp UR; Ullrich A
Nature; 2015 Dec; 528(7583):570-4. PubMed ID: 26675719
[TBL] [Abstract][Full Text] [Related]
10. Role of mTOR Inhibitors in Growth Hormone-Producing Pituitary Adenomas Harboring Different FGFR4 Genotypes.
Jalali S; Monsalves E; Tateno T; Zadeh G
Endocrinology; 2016 Sep; 157(9):3577-87. PubMed ID: 27267848
[TBL] [Abstract][Full Text] [Related]
11. Expression of pituitary tumour-derived, N-terminally truncated isoform of fibroblast growth factor receptor 4 (ptd-FGFR4) correlates with tumour invasiveness but not with G-protein alpha subunit (gsp) mutation in human GH-secreting pituitary adenomas.
Morita K; Takano K; Yasufuku-Takano J; Yamada S; Teramoto A; Takei M; Osamura RY; Sano T; Fujita T
Clin Endocrinol (Oxf); 2008 Mar; 68(3):435-41. PubMed ID: 18070145
[TBL] [Abstract][Full Text] [Related]
12. Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia.
Ezzat S; Zheng L; Asa SL
Mol Endocrinol; 2004 Oct; 18(10):2543-52. PubMed ID: 15231874
[TBL] [Abstract][Full Text] [Related]
13. Loss of heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphism to direct allelic selection in breast cancer.
Zhu X; Zheng L; Asa SL; Ezzat S
Am J Pathol; 2010 Dec; 177(6):2860-9. PubMed ID: 21037081
[TBL] [Abstract][Full Text] [Related]
14. A novel pathway activated by somatostatin receptor type 2 (SST2): Inhibition of pituitary tumor cell migration and invasion through cytoskeleton protein recruitment.
Peverelli E; Giardino E; Treppiedi D; Catalano R; Mangili F; Locatelli M; Lania AG; Arosio M; Spada A; Mantovani G
Int J Cancer; 2018 May; 142(9):1842-1852. PubMed ID: 29226331
[TBL] [Abstract][Full Text] [Related]
15. FGF receptor-4 (FGFR4) polymorphism acts as an activity switch of a membrane type 1 matrix metalloproteinase-FGFR4 complex.
Sugiyama N; Varjosalo M; Meller P; Lohi J; Chan KM; Zhou Z; Alitalo K; Taipale J; Keski-Oja J; Lehti K
Proc Natl Acad Sci U S A; 2010 Sep; 107(36):15786-91. PubMed ID: 20798051
[TBL] [Abstract][Full Text] [Related]
16. Effects of selective somatostatin analogs and cortistatin on cell viability in cultured human non-functioning pituitary adenomas.
Padova H; Rubinfeld H; Hadani M; Cohen ZR; Nass D; Taylor JE; Culler MD; Shimon I
Mol Cell Endocrinol; 2008 May; 286(1-2):214-8. PubMed ID: 18276067
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin analogs regulate tumor corticotrophs growth by reducing ERK1/2 activity.
Treppiedi D; Giardino E; Catalano R; Mangili F; Vercesi P; Sala E; Locatelli M; Arosio M; Spada A; Mantovani G; Peverelli E
Mol Cell Endocrinol; 2019 Mar; 483():31-38. PubMed ID: 30611770
[TBL] [Abstract][Full Text] [Related]
18. Differential antiinflammatory and antinociceptive effects of the somatostatin analogs octreotide and pasireotide in a mouse model of immune-mediated arthritis.
Imhof AK; Glück L; Gajda M; Lupp A; Bräuer R; Schaible HG; Schulz S
Arthritis Rheum; 2011 Aug; 63(8):2352-62. PubMed ID: 21506098
[TBL] [Abstract][Full Text] [Related]
19. Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis.
Ezzat S; Zheng L; Zhu XF; Wu GE; Asa SL
J Clin Invest; 2002 Jan; 109(1):69-78. PubMed ID: 11781352
[TBL] [Abstract][Full Text] [Related]
20. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.
Taylor JG; Cheuk AT; Tsang PS; Chung JY; Song YK; Desai K; Yu Y; Chen QR; Shah K; Youngblood V; Fang J; Kim SY; Yeung C; Helman LJ; Mendoza A; Ngo V; Staudt LM; Wei JS; Khanna C; Catchpoole D; Qualman SJ; Hewitt SM; Merlino G; Chanock SJ; Khan J
J Clin Invest; 2009 Nov; 119(11):3395-407. PubMed ID: 19809159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
